GlassScriptPhysician profile
Kevin H Stroup
NPI 1346229515
$3,717.65
in general payments reported to CMS, 2019-2025
23 companies · $20.10 in 2025
The $20.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $939 · 2021: $1,433 · 2022: $799 · 2023: $60.28 · 2025: $20.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $547.41 | 2019-2022 | |
| Abbvie INC. | $547.19 | 2021-2023 | Qulipta |
| Novo Nordisk INC | $462.14 | 2020-2022 | |
| Glaxosmithkline, LLC. | $408.09 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $349.73 | 2020-2022 | |
| Lilly USA, LLC | $278.81 | 2019-2021 | |
| Allergan, INC. | $231.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.05 | 2020-2022 | |
| Pfizer INC. | $124.51 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $123.03 | 2021-2022 | |
| Janssen Biotech, INC. | $90.49 | 2021 | |
| Merck Sharp & Dohme LLC | $67.95 | 2019-2021 | |
| Dexcom, INC. | $63.19 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $55.09 | 2019-2020 | |
| Amgen INC. | $54.55 | 2021-2025 | Otezla, Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $45.53 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.55 | 2021-2022 | |
| Abbott Laboratories | $24.57 | 2021 | |
| Optos, INC. | $21.62 | 2021 | |
| Daiichi Sankyo INC. | $21.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.10 | 2019 | |
| Astellas Pharma US INC | $18.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Stroup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.